Pricing Log in Create free account
Friday 6 November 2026 Export MANE’s income statement to Excel — free account

Veradermics Incorporated

MANE Healthcare Biotechnology

138.19 9.59 +7.46%
Market cap
$5.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Veradermics Incorporated (MANE) valuation and DCF model

What the price implies · reverse DCF

Veradermics Incorporated is not valued here: free cash flow is negative and there is no revenue to read the price through.

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Biotechnology).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/B 6.87× 6.87× 6.87× 0% above 2.05× 235% above

MANE trades at 6.87× P/B, against a 10-year average of 6.87× (range 6.87×–6.87×). Re-rating to the average implies $138.19 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.